Fusion Antibodies, a UK-based contract research organisation and MAB Discovery, a unique antibody discovery company, have announced their intention to enter into a research and licence agreement in the field of monoclonal antibodies.
Within the scope of this collaboration, Fusion Antibodies will apply our proprietary CDRx™ Multiplex humanization platform to generate therapeutic antibodies, selected and produced by MAB Discovery, who will provide high-quality humanized antibodies ready for further development to potential partners.
“Through this collaboration we are able to create synergies and provide clients with perfect antibody candidates. They will get access to rapid discovery and development of new antibodies through MAB Discovery’s unique immunization and B cell cloning technology. MAB Discovery has developed a rabbit-based platform that produces monoclonal antibodies with unprecedented epitope coverage and potency,” said Dr Paul Kerr, Managing Director, Fusion Antibodies.
“We are very pleased to be working with Fusion Antibodies, a well-respected antibody engineering firm with strong expertise in humanization,” said Dr. Stephan Fischer, Chief Executive Officer of MAB Discovery. “The planned collaboration will enable us to provide our customers added value by offering high-quality humanized antibodies that are ready to be validated and brought into development. We also expect that combining our technologies will reduce the time from target to clinical candidate.”
About MAB Discovery and its technology platform
MAB Discovery is focused on creating a vast repertoire of high quality monoclonal antibodies in terms of potency and epitope coverage for its clients, who include biotech and pharmaceutical companies such as Sanofi, GenMab A/S, Synthon Biopharmaceuticals and others.
MAB Discovery’s proprietary technology utilizes the natural antibody maturation process following immunization. Rather than relying on conventional single hit optimization techniques of a few selected antibodies, the MAB Discovery approach creates a diverse collection of many hundreds of high affinity antibodies. The company uses state-of-the-art automation to select and clone B cells expressing matured antibodies deriving from the immunized animal’s entire repertoire to a given immunogen. Using this sophisticated high throughput approach enables MAB Discovery to select antibodies for functionality at an early stage and not just by simple binding. The MAB Discovery team represents a group of scientists out of Roche Biologicals R&D with extensive experience in developing biologically based therapeutics. For more information, please visit http://www.mabdiscovery.com.
Dr. Paul Kerr, Managing Director
+44(0) 2890 432800
Dr. Stephan Fischer, CEO
+49 89 990 178-0